Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the Children's Cancer Group

Cancer

Volumn 82, Issue 3, 1998, Pages 600-612

  Steinherz, Peter G ^a,k   Gaynon, Paul S ^b   Breneman, John C ^c   Cherlow, Joel M ^d   Grossman, Neil J ^e   Kersey, John H ^f   Johnstone, Helen S ^g   Sather, Harland N ^h   Trigg, Michael E ⁱ   Uckun, Fatih M ^f   Bleyer, W Archie ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d MILLER CHILDREN S HOSPITAL   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k CHILDREN S ONCOLOGY GROUP   (United States)

more..

Author keywords

Acute lymphoblastic leukemia; High risk; Lymphomatous leukemia; Poor prognosis; T cell leukemia

Indexed keywords

ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; HUMANS; INFANT; LEUKEMIA, T-CELL, ACUTE; METHOTREXATE; PREDNISONE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; THIOGUANINE; VINCRISTINE;

EID: 0032006243     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4     Document Type: Article

References (35)

1. Steinherz PG, Siegel SE, Bleyer WA, Kersey J, Chard R Jr., Coccia P, et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure. Cancer 1991;68:751-8.
2. Anderson JR, Wilson JF, Jenkin RDT, Meadows AT, Kersey J, Chilcote RR, et al. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983;308:559-65.
3. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein P, Littman PS, Miller DR, et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features: report of Children's Cancer Study Group, Study CCG-193P. Am J Pediatr Hematol Oncol 1988;10:42-50.
4. Steinherz PG, Gaynon P, Miller DR, Reaman G, Bleyer A, Finklestein J, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - a new intensive therapy protocol: a report from the Children's Cancer Study Group. J Clin Oncol 1986;4:744-52.
5. Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D. CD2 antigen expression on leukemia cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group Study. Blood 1996;88:4288-95.
6. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
8. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer 1977;35:1-39.
9. Breslow N. Comparison of survival curves. In: Buyse M, Staquet M, Sylvester M, editors. Cancer clinical trials: methods and practice. Oxford: Oxford University Press, 1988:381-406.
10. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34:187-20.
11. Breslow N. Analysis of survival data under the proportional hazards model. Int Stat Rev 1975;43:45-58.
12. Steinherz P, Gaynon P, Breneman J, Cherlow JM, Grossman N, Kersey J, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia: the importance of rapid early response. Report from the Children's Cancer Group. J Clin Oncol 1996;14:389-98.
13. Cherlow JM, Steinherz PG, Sather HM, Gaynon P, Grossman N, Kersey J, et al. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Children's Cancer Group. Int J Radiat Oncol Biol Phys 1993;27:1001-9.
14. Hammond D, Sather H, Nesbit M, Miller D, Coccia P, Bleyer A, et al. Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:124-34.
15. Camilla BM, Pinkel D, Thatcher LG, Casper J, Kun LE, Lauer S. Failure of early intensive chemotherapy to improve prognosis in child lymphocytic leukemia. Med Pediatr Oncol 1980;8:383-9.
16. Coccia PF, Bleyer WA, Siegel E, Lukens JN, Gross S, Miller DR, et al. Development and preliminary findings of Children's Cancer Study Group Protocols (#161, 162, 163) for low, average, and high-risk acute lymphoblastic leukemia in children. In: Murphy S, Gilber JR, editors. Leukemia research advances in cell biology and treatment. North Holland: Elsevier, 1983:241-50.
17. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet 1995;345:143-8.
18. Pui C-H. Childhood leukemias. N Engl J Med 1995;332:1618-30.
19. 2 Protocol treatment of stage IV non-Hodgkin's lymphoma in children with partial and extensive bone marrow involvement. Cancer 1983;52:39-43.
20. 2 treatment in 53 children with E-rosette-positive T cell leukemia: results and prognostic factors (A Pediatric Oncology Group Study). Blood 1982;60:1159-68.
21. Lampert F, Henze G, Langermann HJ, Schellong G, Gardner H, Riehm HJ. Acute lymphoblastic leukemia: current status of therapy in children. Recent Results Cancer Res 1984;93: 159-81.
22. Sallan SE. T cell acute lymphoblastic leukemia in children. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K, editors. Haematology and blood transfusion. Volume 26. Modern trends in leukemia IV. Berlin: Springer-Verlag, 1981:121-3.
23. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Children's Cancer Group report. J Clin Oncol 1993;11:520-6.
24. Mott MG, Chessells JM, Willoughby MLN, Mann JR, Morris Jones PH, Malpas JS. Adjuvant low dose radiation in childhood T cell leukemia/lymphoma. Br J Cancer 1984;50:457-62.
25. Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, et al. Prognostic factors in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990;77:166-73.
26. Faletta JM, Schuster JJ, Crist WM, Pullen DJ, Borowitz MJ, Wharam M, et al. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group Study Leukemia 1992;6:541-6.
27. Pui C-H, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990;75:174-9.
28. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abramowitch M, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991;337:61-6.
29. Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 1995;75:1684-93.
30. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-63.
31. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
32. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994;12:740-7.
33. Gaynon PS, Steinherz PG, Bleyer WA, Ablin A, Albo V, Finklestein J, et al. Early superiority of intensive therapy for children with previously untreated acute lymphoblastic leukaemia and unfavorable presenting features. Lancet 1988;2: 921-4.
34. Gaynon PS, Steinherz PG, Bleyer WA, Ablin A, Albo V, Finklestein J, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Study Group Study CCG-106. J Clin Oncol 1993;11:2234-42.
35. Reaman G, Steinherz P, Gaynon P, Bleyer WA, Finklestein J, Evans R, et al. Intensive multi-agent chemotherapy for infants less than one year of age with acute lymphoblastic leukemia. Cancer Treatment Rep 1987;71:1033-8.